First, in BRAF-mutant melanoma cell lines BRAFi treatment results in robust suppression of pERK, whereas in BRAF-mutant CRC cell lines, BRAFi treatment leads to transient pERK suppression for upto 24 h, followed by a rebound in its activity to approximately 40% of the baseline by 48 h (ref. 18). Here, BRAF is linked to melanoma.